(RMD) ResMed - Ratings and Ratios
CPAP, Ventilator, Diagnostic, Software, Cloud
RMD EPS (Earnings per Share)
RMD Revenue
Description: RMD ResMed September 29, 2025
ResMed Inc. (NYSE:RMD) designs, manufactures, and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders worldwide, organized into two primary segments: Sleep & Breathing Health and Residential Care Software.
Its sleep-apnea portfolio includes the ApneaLink Air portable diagnostic unit, the disposable NightOwl device that estimates AHI via peripheral arterial tone and actigraphy, and the EasyCare Tx system for in-lab titration, all of which target clinics, hospitals, and home-care settings.
On the digital side, ResMed offers AirView-a remote-monitoring platform that lets clinicians adjust device settings over the cloud-myAir, a patient-facing app that drives therapy adherence, and a cellular connectivity module that links compatible ventilators to the AirView ecosystem.
Beyond respiratory care, the firm supplies Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN software suites that support home-medical-equipment providers, hospice and home-health agencies, skilled-nursing facilities, and senior-living operators, creating a diversified SaaS revenue stream.
Key metrics (FY 2023): total revenue $3.30 billion, up ~12 % YoY; operating margin 16 %; and recurring SaaS revenue now represents roughly 70 % of total sales, a trend that buffers the business against device-cycle volatility. The global sleep-apnea market is projected to grow at a 6 % CAGR through 2030, driven by aging demographics, rising obesity rates, and expanding tele-health reimbursement policies-factors that underpin ResMed’s growth outlook.
For a deeper, data-driven assessment of ResMed’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
RMD Stock Overview
| Market Cap in USD | 38,712m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1995-06-02 |
RMD Stock Ratings
| Growth Rating | 36.9% |
| Fundamental | 93.8% |
| Dividend Rating | 56.0% |
| Return 12m vs S&P 500 | -15.4% |
| Analyst Rating | 3.95 of 5 |
RMD Dividends
| Dividend Yield 12m | 0.89% |
| Yield on Cost 5y | 1.16% |
| Annual Growth 5y | 6.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.9% |
RMD Growth Ratios
| Growth Correlation 3m | -78% |
| Growth Correlation 12m | 71.3% |
| Growth Correlation 5y | 21.2% |
| CAGR 5y | 6.43% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.15 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.51 |
| Sharpe Ratio 12m | -0.42 |
| Alpha | -14.36 |
| Beta | 0.833 |
| Volatility | 31.26% |
| Current Volume | 2186.9k |
| Average Volume 20d | 891.2k |
| Stop Loss | 239.4 (-3%) |
| Signal | -0.86 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (1.40b TTM) > 0 and > 6% of Revenue (6% = 308.8m TTM) |
| FCFTA 0.20 (>2.0%) and ΔFCFTA 1.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 48.32% (prev 30.89%; Δ 17.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 1.75b > Net Income 1.40b (YES >=105%, WARN >=100%) |
| Net Debt (-327.1m) to EBITDA (1.92b) ratio: -0.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (147.0m) change vs 12m ago -0.34% (target <= -2.0% for YES) |
| Gross Margin 59.36% (prev 56.19%; Δ 3.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.40% (prev 68.18%; Δ 0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 100.2 (EBITDA TTM 1.92b / Interest Expense TTM 16.8m) >= 6 (WARN >= 3) |
Altman Z'' 8.79
| (A) 0.30 = (Total Current Assets 3.51b - Total Current Liabilities 1.02b) / Total Assets 8.17b |
| (B) 0.74 = Retained Earnings (Balance) 6.08b / Total Assets 8.17b |
| (C) 0.22 = EBIT TTM 1.69b / Avg Total Assets 7.52b |
| (D) 2.72 = Book Value of Equity 6.01b / Total Liabilities 2.21b |
| Total Rating: 8.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 93.81
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 4.32% = 2.16 |
| 3. FCF Margin 32.23% = 7.50 |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda -0.17 = 2.50 |
| 6. ROIC - WACC (= 13.81)% = 12.50 |
| 7. RoE 25.51% = 2.13 |
| 8. Rev. Trend 96.29% = 7.22 |
| 9. EPS Trend 96.25% = 4.81 |
What is the price of RMD shares?
Over the past week, the price has changed by -4.86%, over one month by -9.81%, over three months by -9.03% and over the past year by +2.70%.
Is ResMed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RMD is around 211.97 USD . This means that RMD is currently overvalued and has a potential downside of -14.14%.
Is RMD a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 295.8 | 19.8% |
| Analysts Target Price | 295.8 | 19.8% |
| ValueRay Target Price | 237.2 | -3.9% |
RMD Fundamental Data Overview October 26, 2025
P/E Trailing = 27.8423
P/E Forward = 25.9067
P/S = 7.5223
P/B = 6.7651
P/EG = 1.8635
Beta = 0.833
Revenue TTM = 5.15b USD
EBIT TTM = 1.69b USD
EBITDA TTM = 1.92b USD
Long Term Debt = 658.4m USD (from longTermDebt, last quarter)
Short Term Debt = 70.9m USD (from shortTermDebt, last quarter)
Debt = 882.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -327.1m USD (from netDebt column, last quarter)
Enterprise Value = 38.39b USD (38.71b + Debt 882.3m - CCE 1.21b)
Interest Coverage Ratio = 100.2 (Ebit TTM 1.69b / Interest Expense TTM 16.8m)
FCF Yield = 4.32% (FCF TTM 1.66b / Enterprise Value 38.39b)
FCF Margin = 32.23% (FCF TTM 1.66b / Revenue TTM 5.15b)
Net Margin = 27.22% (Net Income TTM 1.40b / Revenue TTM 5.15b)
Gross Margin = 59.36% ((Revenue TTM 5.15b - Cost of Revenue TTM 2.09b) / Revenue TTM)
Gross Margin QoQ = 60.84% (prev 59.33%)
Tobins Q-Ratio = 4.70 (Enterprise Value 38.39b / Total Assets 8.17b)
Interest Expense / Debt = 0.65% (Interest Expense 5.76m / Debt 882.3m)
Taxrate = 17.10% (78.3m / 458.1m)
NOPAT = 1.40b (EBIT 1.69b * (1 - 17.10%))
Current Ratio = 3.44 (Total Current Assets 3.51b / Total Current Liabilities 1.02b)
Debt / Equity = 0.15 (Debt 882.3m / totalStockholderEquity, last quarter 5.97b)
Debt / EBITDA = -0.17 (Net Debt -327.1m / EBITDA 1.92b)
Debt / FCF = -0.20 (Net Debt -327.1m / FCF TTM 1.66b)
Total Stockholder Equity = 5.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.14% (Net Income 1.40b / Total Assets 8.17b)
RoE = 25.51% (Net Income TTM 1.40b / Total Stockholder Equity 5.49b)
RoCE = 27.45% (EBIT 1.69b / Capital Employed (Equity 5.49b + L.T.Debt 658.4m))
RoIC = 22.70% (NOPAT 1.40b / Invested Capital 6.16b)
WACC = 8.89% (E(38.71b)/V(39.59b) * Re(9.08%) + D(882.3m)/V(39.59b) * Rd(0.65%) * (1-Tc(0.17)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 78.15% ; FCFE base≈1.51b ; Y1≈1.86b ; Y5≈3.18b
Fair Price DCF = 305.7 (DCF Value 44.61b / Shares Outstanding 145.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 96.25 | EPS CAGR: 20.99% | SUE: 0.71 | # QB: 0
Revenue Correlation: 96.29 | Revenue CAGR: 13.56% | SUE: 1.04 | # QB: 1
Additional Sources for RMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle